Dual-acting angiotensin II and endothelin receptor blockers show potential as a new class of antihypertensives, with preliminary data indicating they are safe and well tolerated.
Do dual-acting angiotensin II and endothelin receptor blockers reduce systemic blood pressure safely in hypertensive patients?
Dual-acting angiotensin II and endothelin receptor blockers show potential as a new class of antihypertensives by reducing systemic blood pressure safely in preliminary studies.
Endothelin and angiotensin II are potent vasoconstrictor substances that also can exert proliferative and proinflammatory effects. Dysregulation of these systems can induce or mediate endothelial dysfunction and organ damage in systemic hypertension. Dual-acting angiotensin II and endothelin receptor blockers have been shown to reduce systemic blood pressure in animal models and in hypertensive patients. Preliminary data in smaller human studies have shown that these agents are safe and well tolerated. Larger randomized trials evaluating the efficacy and safety of these agents are underway and show potential as a new class of antihypertensives.
Palaniswamy et al. (Wed,) conducted a review in Systemic hypertension. Dual-acting angiotensin II and endothelin receptor blockers was evaluated. Dual-acting angiotensin II and endothelin receptor blockers show potential as a new class of antihypertensives, with preliminary data indicating they are safe and well tolerated.